Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Nussenzweig: Discovery & Characterization of bNAbs |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2014-03-11 |
| Study Made Public: | 2019-07-24 |
Title
A phase 1 open label dose-escalation study of the safety pharmacokinetics and antiretroviral activity of 3BNC117 mAb in HIV-infected and HIV-uninfected volunteers.
Description
CAVD 446 (Protocol # MCA-835) is a Phase 1, open label, dose-escalation study of the safety, pharmacokinetics andantiretroviral activity of 3BNC117 monoclonal antibody in HIV-infected and HIV-uninfected volunteers.
Sign in to see full information about this study and to download study data.